Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Hospira acquires Orchidís generic injectable pharma business
February 2010
SHARING OPTIONS:

LAKE FOREST, Ill.óHospira Inc., a developer of generic injectable pharmaceuticals, announced in January its acquisition of Orchid Chemicals & Pharmaceuticals Ltd.'s generic injectable finished-dosage form pharmaceuticals business for approximately $400 million. Orchid is an Indian developer of bulk actives, formulations and nutraceuticals. The acquisition includes Orchid's beta-lactam antibiotics manufacturing complex and pharmaceutical research and development facility at Irungattukottai, Chennai, as well as its generic injectable product portfolio and pipeline. In addition, the companies signed a long-term exclusive agreement for Orchid to supply active pharmaceutical ingredients for the acquired generic injectable pharmaceuticals business. This agreement builds on the existing product development and commercialization relationship between Hospira and Orchid. 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.